Tag - ANRO

Developments

FDA grants ALTO fast track designation for treatment of CIAS

Alto Neuroscience (NYSE: ANRO) announced that the FDA has granted its novel small molecule PDE4 inhibitor, ALTO-101, fast track designation for the treatment of cognitive impairment associated with schizophrenia (CIAS)...

October 6, 2025

Executive Moves

Alto appoints Dr. Raymond Sanchez to BOD

Alto Neuroscience (NYSE: ANRO) has announced the appointment of industry veteran Raymond Sanchez, MD, to its board of directors (BOD), effective August 12, 2025. Dr. Sanchez brings extensive experience in medicine and...

August 13, 2025

Developments

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...

July 16, 2024

Tag - ANRO

FDA grants ALTO fast track designation for treatment of CIAS

Alto appoints Dr. Raymond Sanchez to BOD

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Subscribe